Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 21;13:1221352. doi: 10.3389/fonc.2023.1221352

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Tanaka, Enokida, Okano, Fujisawa, Tanaka, Takeshita, Onaga, Hoshi, Wada, Sato, Ueda and Tahara

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representative images from a patient with recurrent oral gingival squamous cell carcinoma who achieved a favorable clinical response by PE-based chemotherapy after pembrolizumab failure. (A) Multiple subcutaneous and retroperitoneum tumors progressed after pembrolizumab treatment. (B) Tumor promptly responded to PCE therapy, and the response reached PR two weeks after the initiation of PCE. (C) Tumors almost disappeared, and the pathological complete response of the buttock tumor was proven by surgery for wound closure. PCE, paclitaxel+carboplatin+cetuximab; pCR, pathological complete response. Notes: PE-based chemotherapy, paclitaxel+carboplatin+cetuximab (PCE) or paclitaxel+cetuximab (PTX+Cmab).